Cambodia vs Guatemala: Average cost of multi drug-resistant tuberculosis treatment
Cambodia
850 constant 2022 US$
in 2024
Guatemala
813 constant 2022 US$
in 2024
Cambodia rank
58th
Guatemala rank
61st
Average cost of multi drug-resistant tuberculosis treatment over time
- Cambodia
- Guatemala
How they compare
Cambodia currently reports 850 constant 2022 US$ against 813 constant 2022 US$ in Guatemala, a difference of 37 constant 2022 US$.
Across all 7 years both countries report, Cambodia has been ahead every year.
Cambodia ranks 58th and Guatemala ranks 61st of 92 countries.
Cambodia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cambodia | Guatemala | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,247 constant 2022 US$ | 784.33 constant 2022 US$ | 1,463 constant 2022 US$ | Cambodia |
| 2020s | 1,688 constant 2022 US$ | 786.5 constant 2022 US$ | 901 constant 2022 US$ | Cambodia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cambodia or Guatemala?
- Cambodia, at 850 constant 2022 US$ against 813 constant 2022 US$ in Guatemala as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cambodia and Guatemala?
- 37 constant 2022 US$, with Cambodia ahead.
- How many years of comparable data are there for Cambodia and Guatemala?
- 7 years are reported by both, from 2017 to 2024.
- How do Cambodia and Guatemala rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cambodia ranks 58th and Guatemala ranks 61st of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.